On May 23, the FDA approved a new drug intended to treat hospital-acquired pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus, a critical bacterial pathogen. 

The American Hospital Association and American Society of Health-System Pharmacists, along with four other groups, recently sent a letter to the House Energy and Commerce Committee's Health Subcommittee opposing two bill amendments that would affect 340B hospitals and stakeholders.

Moderna has purchased a new biomanufacturing facility in Marlborough, Mass., which will be designated for mRNA manufacturing. It is anticipated to open in September 2024, according to an April 28 report from the Worcester Business Journal. 

A pill version of Ozempic (semaglutide), a Type 2 diabetes drug in high demand for its off-label use for weight loss, resulted in 15.1 percent weight loss among phase 3 study participants. 

In U.S. News' newest over-the-counter medicine and health products ranking, the news organization collaborated with The Harris Poll to determine what 350 pharmacists recommend among more than 700 products. 

One pharmacy benefit manager makes up one-third of the market, according to a May 23 report from Drug Channels. 

Teva Pharmaceuticals said it will shrink some of its generic drug manufacturing as the Israel-based drugmaker reports $20.7 billion in debt. 

The American Society of Health-System Pharmacists has announced the inaugural launch of a national membership organization aimed at supporting and advocating for policies that advance the role of pharmacist technicians in patient care.

The FDA on May 19 approved the first drug to treat patients with dystrophic epidermolysis bullosa — a rare genetic disorder that causes fragile skin and persistent sores. 

Corewell Health, based in Grand Rapids and Southfield, Mich., named Jason McCarthy, PharmD, as its next chief pharmacy officer May 17.